Articles tagged with Narcolepsy
Researchers found significant loss of neurons in the locus coeruleus, a second critical region involved in arousal and muscle tone regulation. This finding suggests an immune-mediated process and challenges the prevailing explanation for narcolepsy with cataplexy.
A new clinical trial found that solriamfetol helped early morning shift workers with shift work disorder stay more alert and report better overall functioning. The study, published in NEJM Evidence, enrolled 78 early-morning shift workers and showed significant improvement in sleepiness and daily activities after four weeks of treatment.
A comprehensive review synthesizes current insights into the intricate connections between gut microbiota and sleep regulation, highlighting the crucial role of peripheral organs in modulating brain function and behavior. Disruptions in gut microbiota composition are closely linked to sleep disturbances across multiple disorders.
Researchers found that narcolepsy patients exhibit similar slow brain pulsations to healthy individuals during sleep, but with distinct differences in intensity. The study suggests that orexin may suppress brain pulsations, linked to impaired brain clearance, a potential target for treatment.
A narrative review of over 1,700 papers found only seven papers addressing dexamphetamine addiction directly. The study raises questions about the evidence underpinning its restriction by regulatory agencies. Dexamphetamine is effective in treating ADHD and narcolepsy but may have benefits in treating obesity.
A new therapeutic approach combining cognitive behavioral therapy (CBT) and lucid dreaming has shown promise in reducing nightmare severity and frequency in patients with narcolepsy. The study, published in the Journal of Sleep Research, found overall reductions in nightmare symptoms in all six participants tested.
Studies in mice reveal that orexin plays a key role in deciding between physical activity and consuming food, particularly when both options are available. By understanding this process, scientists aim to develop strategies to overcome exercise barriers and address the global obesity epidemic.
Two new studies show that people with narcolepsy have a significantly higher risk of cardiovascular disease and adverse cardiac events. The research found a 77% increased risk of any cardiovascular disease and an 82% increased risk of major adverse cardiovascular events.
Researchers have discovered that clown loaches and zebrafish can control their sleep-wake rhythm without relying on orexin, contradicting the long-held assumption that vertebrates share similar mechanisms. This finding reshapes our understanding of sleep and wake regulation in vertebrates.
Researchers found that ordinary sleepers can pick up verbal information and respond to it by contracting facial muscles, even during most stages of sleep. The study suggests that standardized communication protocols may be possible with sleeping individuals to better understand mental activity changes during sleep.
Researchers at ETH Zurich discovered that orexin neurons directly influence emotional state through pupil size. This finding opens new avenues for medical treatment and diagnosis of sleep disorders like narcolepsy and other neurological conditions.
Researchers have discovered a new sleep molecule, microRNA-137 (miR-137), that regulates hypocretin levels for normal sleep. The study found that miR-137 is associated with hypocretin regulation and sleep disorders such as narcolepsy and insomnia.
Researchers found that a temporary increase in dopamine levels in the basolateral amygdala initiates transitions from non-rapid eye movement (NREM) to rapid eye movement (REM) sleep. This discovery may have important implications for understanding changes in sleep state and treating conditions like cataplexy and narcolepsy.
Scientists have developed a genetically encoded biosensor called OxLight1, which enables them to study the action and release mechanisms of neuropeptides like orexin in living mice. The researchers found that the level of orexin release correlates with neuronal activity, revealing previously invisible aspects of healthy brain function.
UCLA researchers found that removing brain cells linked to wakefulness and addiction reduces both physical and emotional symptoms of opioid withdrawal. The study suggests that drug therapies regulating hypocretin production may be an effective treatment for opiate addiction and withdrawal.
Researchers have identified a novel autoantigen in narcolepsy, which mimics a protein from the H1N1 virus. Immune cells in narcolepsy patients mounted stronger responses against viral peptides and human proteins, leading to the discovery of a self-protein that triggers an autoimmune response.
Researchers have discovered autoreactive cells in narcolepsy patients, providing new proof that the sleep disorder is an autoimmune disease. Autoreactivity was found not only in patients but also in healthy individuals, suggesting a trigger for the disease.
Researchers found that people with heroin addiction have 54% more hypocretin-producing neurons than non-addicts. In mice, morphine restored missing hypocretin cells, reversing narcoleptic symptoms. Further study is needed to explore potential treatment for narcolepsy.
Researchers discovered heroin addicts have more hypocretin-producing neurons than controls, while morphine reversed cataplexy symptoms in narcoleptic mice. Increasing hypocretin levels may serve as a treatment strategy for narcolepsy and potentially combat opiate addiction.
Researchers have successfully developed a non-peptide compound that promotes wakefulness and remedies narcoleptic symptoms in mouse models. The compound, YNT-185, penetrates the blood-brain barrier and induces significant wakefulness without desensitization or sleep rebounds.
A recent study led by Kanazawa University has discovered that serotonin neurons in the dorsal raphe nucleus inhibit catalepsy by reducing activities of the amygdala that controls emotion. This finding provides new insights into the narcolepsy mechanism and holds promise for developing new therapies for cataplexy.
A Stanford study found that narcolepsy may be triggered by a combination of genetic predisposition and infection, particularly with the H1N1 virus. Researchers discovered elevated antibodies in patients who received the Pandemrix flu vaccine, which was associated with an increased risk of narcolepsy.
Researchers have found that narcolepsy bears the hallmarks of a classic autoimmune disorder, with a particular autoantibody process triggering the loss of orexin neurons. This discovery opens up new avenues for diagnosis and treatment, potentially leading to a better understanding of the disease.
A new study reveals that nearly half of adolescents with excessive daytime sleepiness consistent with a diagnosis of narcolepsy test positive for marijuana, emphasizing the need for drug screening. The study's findings also suggest that marijuana use may be contributing to misdiagnoses of narcolepsy in teens.
A study by Nationwide Children's Hospital found that 43% of children with positive marijuana urine screens had test results consistent with narcolepsy or abnormal REM sleep patterns. The study highlights the importance of obtaining a urine drug screen before accepting a diagnosis of narcolepsy in adolescents.
Neuroscientists at SRI International have found that a form of baclofen works better at treating narcolepsy than the best drug currently available when tested in mice. The research team also presents a mouse model of narcolepsy that mimics the human disorder, allowing for more precise control of hypocretin/orexin neuron loss and potent...
A Swedish cohort study found a strong association between the Pandemrix anti-swine flu vaccine and an increased risk of narcolepsy in individuals under 20 years old. The study also detected a trend towards increased risk in young adults between 21-30.
A new study has identified a nearly 100% association between narcolepsy and a specific gene variant, suggesting a causal role for the HLA DQB1*06:02 allele in the disease. The findings support the idea that immune system dysfunction plays a key role in narcolepsy development.
A new study suggests that H1N1 infection can trigger autoimmune destruction of brain cells producing wakefulness protein hypocretin, leading to narcolepsy. Researchers believe that molecular mimicry between the virus and human protein may play a key role in the disease's development.
Researchers at UCLA have found a possible link between histamine cells and the loss of hypocretin neurons in people with narcolepsy. The study suggests that an excess of histamine cells may cause the destruction of hypocretin cells, which is thought to contribute to the sleep disorder.
A new study found that people with narcolepsy have a large increase in the number of neurons producing histamine, which may contribute to symptoms like preserved consciousness during cataplexy and fragmented nighttime sleep. This discovery suggests that drugs reducing histamine signaling at night may improve sleep in narcolepsy.
A study found a 14-fold increased risk of narcolepsy after receiving the AS03 adjuvanted pandemic A/H1N1 2009 vaccine, with vaccination within six months associated with an even higher risk. The authors suggest that the true risk may be lower due to delayed diagnosis.
A Finnish study found that the Pandemrix vaccine used during the 2009 H1N1 pandemic was associated with a significant increase in childhood narcolepsy. The vaccine's AS03 adjuvant was linked to an abrupt rise in incidence rates, especially among vaccinated children under 19.
Researchers found that narcoleptic patients have a deficiency of the neuropeptide hormone orexin, leading to impaired brown fat activity. This can result in excessive weight gain despite reduced caloric intake.
A new study links an inherited mutation in the myelin oligodendrocyte gene (MOG) to rare forms of narcolepsy and multiple neuropsychiatric disorders. The research identifies a unique mutation present only in affected family members, highlighting the role of MOG in disease susceptibility.
Researchers found a seasonal pattern of narcolepsy onset in China, most frequent in April, with a significant spike following the H1N1 pandemic. The study suggests that flu vaccination was unlikely to cause the increase and points towards an autoimmune disease trigger.
A new Stanford study found a significant correlation between narcolepsy onset and seasonal H1N1 infections, suggesting that getting vaccinated may provide protection. The study of over 900 patients in China revealed a five-to-seven month delay between flu/cold outbreaks and narcolepsy cases, with the disease most frequent in April.
The study found that individuals with untreated hypersomnia incur significant economic costs, including increased medication use, hospital admissions, and unemployment. The researchers estimate that each person with violent snoring or narcolepsy costs society approximately €10,223 per year.
A study found that individuals with a specific gene variant respond differently to sleep deprivation, experiencing more fatigue and fragmented sleep. The findings have implications for understanding individual responses to sleep loss and may help inform strategies for mitigating its effects.
A new study identifies autoantibodies targeting Trib2 protein in narcolepsy patients with cataplexy, supporting the theory that narcolepsy is an autoimmune disorder. Elevated levels of these antibodies were found in narcolepsy patients, furthering research on the underlying causes of the condition.
Researchers confirm that narcolepsy is an autoimmune disease caused by a specific immune cell variation. A study found that nearly 90% of patients with narcolepsy carry a variant of the human leukocyte antigen gene, which is also associated with other autoimmune diseases like multiple sclerosis and juvenile diabetes.
A recent genetic study has confirmed the immune system's role in narcolepsy, revealing that autoimmunity plays a crucial part in the disorder. The study found unique variants of genes HLA-DQB1*0602 and TCRA associated with narcolepsy-cataplexy.
A new study from McGill University finds that MCH neurons are activated during sleep and could be important in regulating the sleep state. The study provides deeper understanding of the sleep-wake cycle and vital insight into the basis of sleep disorders such as narcolepsy.
A new study highlights the dangers of nicotine use among narcoleptics, who are at a higher risk of burns and nicotine addiction due to excessive sleepiness. The study found that 75% of respondents experienced burns while smoking, and many struggled to quit due to worsening sleepiness.
A new study published in the journal Sleep reveals that narcolepsy patients have a high prevalence of eating disorders, with half reporting persistent cravings and binge eating. The study also found no correlation between weight gain and binge eating, suggesting metabolic alterations may be involved.
Researchers found that increasing core body temperature improved vigilance, while decreasing skin temperature enhanced wakefulness in narcoleptic subjects. The study used a thermosuit to manipulate skin temperature and hot or cold food/drinks to adjust core body temperature.
The American Academy of Sleep Medicine has updated its practice parameters for the treatment of narcolepsy and other central hypersomnias. The guidelines recommend a comprehensive approach to managing symptoms, including modafinil, sodium oxybate, and tricyclic antidepressants. Regular follow-up with healthcare providers is crucial to ...
Researchers have found a genetic mutation in zebrafish that causes insomnia, providing a new animal model for studying sleep disorders. The study reveals that zebrafish experience reduced overall sleep and shorter sleep duration compared to normal fish.
A new study suggests that narcolepsy patients are more likely to be overweight due to lower metabolism and changes in eating behavior. The study found that narcoleptic patients had lower body mass index (BMI) scores than healthy controls, indicating a positive energy balance.
A study found that persons with narcolepsy with cataplexy have significantly lower levels of CSF hypocretin-1 than those without cataplexy or other conditions. Patients with low hypocretin-1 values experienced more severe cataplectic attacks.
Researchers found that the MX2 gene is significantly down-regulated in narcoleptic patients' white blood cells, which may contribute to immune system abnormalities. This discovery could help elucidate the pathophysiology of narcolepsy and inform further studies on its functional relationship with the MX2 gene.
A study published in the journal SLEEP found that narcoleptics have a high frequency of REM sleep without atonia, leading to abnormal muscle activity. In contrast, patients with idiopathic REM sleep behavior disorder (RBD) had a higher percentage of REM sleep without atonia but lower REM density.
A study found that 38.4% of police officers screened positive for sleep disorders, including OSA, insomnia, and shift work sleep disorder. This high incidence may be linked to chronic sleep loss due to irregular schedules.
Parkinson's disease and narcolepsy share symptoms due to damage in the same small group of neurons. Researchers found that Parkinson's patients have severe loss of hypocretin cells, which may be reversible with treatments aimed at reversing this deficit.
A study published in the SLEEP journal found that brain areas hyperactivated during cataplexy in a narcoleptic patient resemble those active during normal REM sleep, but without other characteristic features. This discovery may help explain how narcolepsy's cataplexy symptom occurs.
A comprehensive review published in the journal SLEEP found that environmental exposures before the age of onset in genetically susceptible individuals may contribute to the development of narcolepsy. The study suggests intensifying the search for these exposures and focusing on the first two decades of life to prevent the disease.
A study published in The Lancet found an underlying autoimmune process linked to narcolepsy in people with a certain genetic profile. This breakthrough could lead to improved disease treatment and earlier diagnosis using a clinically useful assay.
Researchers found that histamine cell activity continues during cataplexy, while norepinephrine and serotonin cell activity ceases, leading to loss of muscle tone. The study sheds light on the biological causes of narcolepsy and may aid in developing drugs to induce sleep and increase alertness.
The study reveals that histamine-triggered neurons maintain normal waking-level activity during cataplexy and are not affected by drugs that increase the condition. The findings also suggest a link between hypocretins, which govern wakefulness, and the effect of these proteins on histamine cells.
Researchers at UT Southwestern Medical Center have discovered a potentially new avenue for treating human narcolepsy by introducing the brain chemical orexin into genetically engineered mice. The study, which uses knockout mice that lack orexin-producing cells, finds that artificially reintroducing orexin alleviates narcoleptic symptom...